BChE-IN-56
BChE-IN-56 is a blood-brain barrier-penetrant BChE inhibitor. BChE-IN-56 covalently carbamoylates the catalytic serine Ser198, producing pseudo-irreversible inhibition, with an IC50 of 18.2 nM and a Ki of 416 nM against hBChE. BChE-IN-56 improves cognitive performance in mouse models of cognitive impairment without inducing motor deficits. BChE-IN-56 can be used for research on Alzheimer's disease.
For research use only. We do not sell to patients.
- CAS No.: 3137514-33-8
- Formula: C20H24N2O2
- Molecular Weight:324.42
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
hBCHE 18.2 nM (IC50) |
hAChE 71330 nM (IC50) |
hBCHE 416 nM (Ki) |
In Vitro
BChE-IN-56 has a protein binding rate of 85.92% in human plasma; it is stable in human plasma with a half-life of 278.00 min[1].
BChE-IN-56 has a half-life of 38.72 min in human liver microsomes, with an intrinsic clearance of 35.84 μL/min/mg protein; it has a half-life of 68.2 min in human hepatocytes, with an intrinsic clearance of 14.7 μL/min/million cells[1].
BChE-IN-56 is metabolized in human hepatocytes through pathways including deamination, deformylation, dealkylation, desaturation, oxidation, methylation, acetylation, and glucoside conjugation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Albino Swiss (CD-1) (adult male, 18-22 g, induced by Scopolamine hydrobromide (HY-N0296A) (1 mg/kg, s.c.))[1]
-
Dosage:5 mg/kg; 10 mg/kg; 30 mg/kg
-
Administration:i.p.; single administration 60 min before testing
-
Result:Produced longer step‑through latency during the retention trial in the PA task for the 10 and 30 mg/kg doses compared with scopolamine‑treated control mice; the 5 mg/kg dose exerted no effect.
Elicited preference for the novel object and a high discrimination index comparable to vehicle‑treated mice across 5, 10, and 30 mg/kg doses in the NOR task, whereas scopolamine‑treated control mice displayed a negative discrimination index.
Parmacokinetics
| Species | Dose | Route | Cmax | Cmax (Brain) | Tmax (Plasma) | Tmax (Brain) |
|---|---|---|---|---|---|---|
| Mice[1] | 10 mg/kg | i.p. | 1270.58 nM | 779.50 nM | 5.00 min | 10.00 min |
Chemical Information
-
CAS No. 3137514-33-8
-
Molecular Weight 324.42
-
Formula C20H24N2O2
-
SMILES
CC1=CC=CC=C1NC(OC[C@@H]2CN(CC3=CC=CC=C3)CC2)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)